Walder Wyss advises Pfizer on its investment in Anokion

As we have informed here last 10 November 2022, the clinical-stage biotechnology company Anokion has closed an USD 35 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative. The Biotech company is focus on the treating autoimmune disease by restoring normal immune tolerance.

Walder Wyss has also advised on the deal acting as Swiss legal advisor to Pfizer. The team included Urs Schenker (counsel, pictured left), Samuel Lieberherr (managing associate, pictured center) and Timon Nydegger (senior associate, pictured right), all corporate/m&a.

Walder Wyss advises Pfizer on its investment in Anokion

mercedes.galan

Legalcommunity.ch

Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio

SHARE

Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram